An important new study has surfaced stating injectable contraceptives ( progestin-only birth control) can double the risk of breast cancer in young women after only a year or so of use!
Of course there are a ton of studies that come out every month it seems saying this BC pill will give you a higher risk of this and that.. but it's something to always consider if you are using a form of BC..3.2% of women using contraception in the U.S use this kind of injectable contraception.
I have a friend who uses "injectable contraceptives".. she said she's a fan because you get it done and then don't have to worry about forgetting to take a little pill at the same time everyday ( which to be honest I still strongly believe is a myth gynos tell you so you won't forget to take it)..
But don't be confused over the studies big technical term depo-medroxyprogesterone acetate, it's just what researches believe is the harmful link between the increased risk.. if you want to ask your doctor about it, it goes by DMPA.
So read on and enlighten yourself...
ABSTRACT
Depo-medroxyprogesterone acetate (DMPA) is an injectable contraceptive that contains
the same progestin as the menopausal hormone therapy regimen found to increase
breast cancer risk among postmenopausal women in the Women's Health Initiative
clinical trial. However, few studies have evaluated the relationship between DMPA use
and breast cancer risk. Here we conducted a population-based case-control study
among 1028 women 20-44 years of age to assess the association between DMPA use
and breast cancer risk. Detailed information on DMPA use and other relevant covariates
was obtained through structured interviewer administered in-person questionnaires, and
unconditional logistic regression was used to evaluate associations between various
aspects of DMPA use and breast cancer risk. We found that recent DMPA use for 12
months or longer was associated with a 2.2-fold (95% CI: 1.2-4.2) increased risk of
invasive breast cancer. This risk did not vary appreciably by tumor stage, size, hormone
receptor expression, or histological subtype. Although breast cancer is rare among
young women and the elevated risk of breast cancer associated with DMPA appears to
dissipate after discontinuation of use, our findings emphasize the importance of
identifying the potential risks associated with specific forms of contraceptives given the
number of available alternatives
Full Study: http://cancerres.aacrjournals.org/content/early/2012/02/25/0008-5472.CAN-11-4064.full.pdf+html?sid=1b3d9747-67b8-4afc-bcc3-79c94e99d444
No comments:
Post a Comment